What is VRDN's last price and market cap on Chartloom?

The overview shows a last price near n/a and market cap near 2.11B (subject to data latency), alongside the price snapshot and profile on this page.

What P/E and 52-week range are shown for VRDN?

P/E (TTM) is n/a and 52-week range is $13.18 to $34.29 when available from the data feed; see the metrics and chart on this page.

Where do Chartloom’s VRDN figures come from?

Figures are compiled from market data and SEC-backed fundamentals used in the app. Use primary filings and a broker for trading decisions.

What trailing-twelve-month financials does Chartloom show for VRDN?

The company profile lists revenue (TTM) near $73M, net income (TTM) near $-39.61B, EPS (TTM) near $-3.90 when available from the market-data feed. Figures are informational and may lag live markets.

Where is Viridian Therapeutics Inc based, and what identifiers does Chartloom list?

The company context section lists headquarters in Waltham, Massachusetts, US, 110.4M shares outstanding, ISIN US92790C1045 when available from company profile and filing metadata.

Viridian Therapeutics Inc

$VRDN

Health Care · Biotechnology

IR Run Scenarios

$18.66

+1.74%

Overview AI Summary Charts Financials Valuation

Profile

Read AI summary

Viridian Therapeutics, Inc. is a biopharmaceutical company that develops medicines for autoimmune and rare diseases. The company is headquartered in Waltham, Massachusetts and currently employs 252 full-time employees. The company went IPO on 2014-06-18. The firm is advancing multiple candidates in the clinic for the treatment of patients with thyroid eye disease (TED). The firm is conducting two global Phase 3 clinical trials (THRIVE and THRIVE-2) to evaluate the safety and efficacy of veligrotug in patients with active and chronic TED. The company is also conducting two global Phase 3 clinical trials, REVEAL-1 and REVEAL-2, to evaluate the efficacy and safety of VRDN-003 in patients. Its advanced program, veligrotug, is a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered for the treatment of TED. In addition to its TED portfolio, the Company is advancing a novel portfolio of neonatal Fc receptor (FcRn) inhibitors, including VRDN-006 and VRDN-008, which has the potential to be developed in multiple autoimmune diseases.

Employees

252

Website

www.viridiantherapeutics.com/

IPO

2014-06-18

Beta

Next earnings date

—

Financials & valuation

Open valuation

Revenue (TTM)